111 related articles for article (PubMed ID: 24767791)
1. Therapeutic use of H2O2-responsive anti-oxidant polymer nanoparticles for doxorubicin-induced cardiomyopathy.
Park S; Yoon J; Bae S; Park M; Kang C; Ke Q; Lee D; Kang PM
Biomaterials; 2014 Jul; 35(22):5944-53. PubMed ID: 24767791
[TBL] [Abstract][Full Text] [Related]
2. H2O2-responsive molecularly engineered polymer nanoparticles as ischemia/reperfusion-targeted nanotherapeutic agents.
Lee D; Bae S; Hong D; Lim H; Yoon JH; Hwang O; Park S; Ke Q; Khang G; Kang PM
Sci Rep; 2013; 3():2233. PubMed ID: 23868607
[TBL] [Abstract][Full Text] [Related]
3. Hydrogen peroxide-responsive copolyoxalate nanoparticles for detection and therapy of ischemia-reperfusion injury.
Lee D; Bae S; Ke Q; Lee J; Song B; Karumanchi SA; Khang G; Choi HS; Kang PM
J Control Release; 2013 Dec; 172(3):1102-10. PubMed ID: 24096013
[TBL] [Abstract][Full Text] [Related]
4. Ultrasound imaging and on-demand therapy of peripheral arterial diseases using H
Jung E; Noh J; Kang C; Yoo D; Song C; Lee D
Biomaterials; 2018 Oct; 179():175-185. PubMed ID: 29990676
[TBL] [Abstract][Full Text] [Related]
5. Hydrogen Peroxide-Responsive Nanoparticle Reduces Myocardial Ischemia/Reperfusion Injury.
Bae S; Park M; Kang C; Dilmen S; Kang TH; Kang DG; Ke Q; Lee SU; Lee D; Kang PM
J Am Heart Assoc; 2016 Nov; 5(11):. PubMed ID: 27930351
[TBL] [Abstract][Full Text] [Related]
6. H2O2-responsive antioxidant polymeric nanoparticles as therapeutic agents for peripheral arterial disease.
Kwon B; Kang C; Kim J; Yoo D; Cho BR; Kang PM; Lee D
Int J Pharm; 2016 Sep; 511(2):1022-32. PubMed ID: 27521705
[TBL] [Abstract][Full Text] [Related]
7. Porous antioxidant polymer microparticles as therapeutic systems for the airway inflammatory diseases.
Jeong D; Kang C; Jung E; Yoo D; Wu D; Lee D
J Control Release; 2016 Jul; 233():72-80. PubMed ID: 27151077
[TBL] [Abstract][Full Text] [Related]
8. H2O2-Responsive Antioxidant Nanoparticle Attenuates Whole Body Ischemia/Reperfusion-Induced Multi-Organ Damages.
Li R; Rhee SJ; Bae S; Su S; Kang CS; Ke Q; Koo YE; Ryu C; Song CG; Lee D; Kang PM
J Cardiovasc Pharmacol Ther; 2021 May; 26(3):279-288. PubMed ID: 33111565
[TBL] [Abstract][Full Text] [Related]
9. Antioxidant polymeric prodrug microparticles as a therapeutic system for acute liver failure.
Ko E; Jeong D; Kim J; Park S; Khang G; Lee D
Biomaterials; 2014 Apr; 35(12):3895-902. PubMed ID: 24508370
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Inflammation-Associated Thrombosis with ROS-Responsive Heparin-DOCA/PVAX Nanoparticles.
Xiang Z; Wang Y; Ma Z; Xin Z; Chen R; Shi Q; Wong SC; Yin J
Macromol Biosci; 2019 Aug; 19(8):e1900112. PubMed ID: 31222912
[TBL] [Abstract][Full Text] [Related]
11. Reduction of oxidative stress by p-hydroxybenzyl alcohol-containing biodegradable polyoxalate nanoparticulate antioxidant.
Kim S; Park H; Song Y; Hong D; Kim O; Jo E; Khang G; Lee D
Biomaterials; 2011 Apr; 32(11):3021-9. PubMed ID: 21292318
[TBL] [Abstract][Full Text] [Related]
12. H2O2-triggered bubble generating antioxidant polymeric nanoparticles as ischemia/reperfusion targeted nanotheranostics.
Kang C; Cho W; Park M; Kim J; Park S; Shin D; Song C; Lee D
Biomaterials; 2016 Apr; 85():195-203. PubMed ID: 26874282
[TBL] [Abstract][Full Text] [Related]
13. Hydrogen peroxide-activatable antioxidant prodrug as a targeted therapeutic agent for ischemia-reperfusion injury.
Lee D; Park S; Bae S; Jeong D; Park M; Kang C; Yoo W; Samad MA; Ke Q; Khang G; Kang PM
Sci Rep; 2015 Nov; 5():16592. PubMed ID: 26563741
[TBL] [Abstract][Full Text] [Related]
14. Regulation of kinase cascade activation and heat shock protein expression by poly(ADP-ribose) polymerase inhibition in doxorubicin-induced heart failure.
Bartha E; Solti I; Szabo A; Olah G; Magyar K; Szabados E; Kalai T; Hideg K; Toth K; Gero D; Szabo C; Sumegi B; Halmosi R
J Cardiovasc Pharmacol; 2011 Oct; 58(4):380-91. PubMed ID: 21697725
[TBL] [Abstract][Full Text] [Related]
15. Absence of thrombospondin-2 increases cardiomyocyte damage and matrix disruption in doxorubicin-induced cardiomyopathy.
van Almen GC; Swinnen M; Carai P; Verhesen W; Cleutjens JP; D'hooge J; Verheyen FK; Pinto YM; Schroen B; Carmeliet P; Heymans S
J Mol Cell Cardiol; 2011 Sep; 51(3):318-28. PubMed ID: 21624372
[TBL] [Abstract][Full Text] [Related]
16. Ultrasonographic Imaging and Anti-inflammatory Therapy of Muscle and Tendon Injuries Using Polymer Nanoparticles.
Kim GW; Kang C; Oh YB; Ko MH; Seo JH; Lee D
Theranostics; 2017; 7(9):2463-2476. PubMed ID: 28744328
[TBL] [Abstract][Full Text] [Related]
17. Modulation of doxorubicin-induced cardiac dysfunction in toll-like receptor-2-knockout mice.
Nozaki N; Shishido T; Takeishi Y; Kubota I
Circulation; 2004 Nov; 110(18):2869-74. PubMed ID: 15505089
[TBL] [Abstract][Full Text] [Related]
18. Doxorubicin-induced apoptosis: implications in cardiotoxicity.
Kalyanaraman B; Joseph J; Kalivendi S; Wang S; Konorev E; Kotamraju S
Mol Cell Biochem; 2002; 234-235(1-2):119-24. PubMed ID: 12162424
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of monomethoxy poly(ethylene glycol)-poly (ε-caprolactone) micelle-encapsulated doxorubicin against mouse melanoma.
Zheng L; Gou M; Zhou S; Yi T; Zhong Q; Li Z; He X; Chen X; Zhou L; Wei Y; Qian Z; Zhao X
Oncol Rep; 2011 Jun; 25(6):1557-64. PubMed ID: 21455590
[TBL] [Abstract][Full Text] [Related]
20. Poly(ADP-ribose) polymerase-2 depletion reduces doxorubicin-induced damage through SIRT1 induction.
Szántó M; Rutkai I; Hegedus C; Czikora Á; Rózsahegyi M; Kiss B; Virág L; Gergely P; Tóth A; Bai P
Cardiovasc Res; 2011 Dec; 92(3):430-8. PubMed ID: 21921080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
